Brain

Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity

BOSTON and ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical…

10 months ago

AlzeCure presents positive phase II clinical data with ACD440 against neuropathic pain at EFIC 2023 Conference

STOCKHOLM, SE / ACCESSWIRE / September 20, 2023 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR),…

10 months ago

Red Light Holland: Mistercap’s Launches Organic Grow-Your-Own Mushroom Kits for Sale at www.Mistercap.com

Toronto, Ontario--(Newsfile Corp. - September 19, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light…

10 months ago

CANAQUEST Announces Award of European Cannabinoid Patent

EU Patent #19846183.2 - A NOVEL BOTANICAL AND TETRAHYDROCANNABINOL ("THC") FORMULATION FOR THE REDUCTION OF CANNABIS-INDUCED NEGATIVE NEUROPSYCHIATRIC SIDE-EFFECTSWe believe…

10 months ago

Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel,…

10 months ago

Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…

10 months ago

FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated

TORONTO, ON / ACCESSWIRE / September 18, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…

10 months ago

Aruna Bio Announces Presentation on the Mechanism of its Neural Exosome Platform and Lead Program, AB126, at the BioProcess International Conference & Exhibition

– AB126, an unmodified exosome derived from neural stem cells, shows native therapeutic activity with anti-inflammatory and neuroprotective properties through modulation…

10 months ago

Safety Shot to Develop Detox Product for Alcohol Poising, Plans to File IND with U.S. FDA

Concentrated form of Safety Shot may be effective as a rapid treatment for alcohol poising which causes 2,200 deaths each…

10 months ago

AlzeCure Gets an Abstract on Phase II Clinical Data with ACD440 for Neuropathic Pain Accepted at Pain Conference

STOCKHOLM, SWEDEN / ACCESSWIRE / September 18, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), )…

10 months ago